Erik Eliasson

Erik Eliasson is a Professor and Senior Physician at Karolinska Institutet, leading the Drug treatment research group within the Department of Laboratory Medicine. His work focuses on precision medicine, particularly optimizing drug treatment based on genetic and individual variability. He holds a University Medical Degree from Karolinska Institutet (1994) and became a Docent in 2000.

Research Interests: His research emphasizes pharmacogenomics, drug metabolism, and individualized therapy. Key areas include predicting drug response in breast cancer patients via CYP2D6 genotyping, optimizing antibiotic dosing in critically ill patients, and studying pharmacokinetics of antituberculosis drugs. Collaborations span oncology, clinical pharmacology, and infectious diseases.

Publications: Recent work highlights PharmFreq (a pharmacogenetic atlas), CYP2D6 genotype effects on tamoxifen therapy, and suboptimal antibiotic exposure in tuberculosis patients. Articles often bridge clinical practice with genetic insights.

Awards: No specific honors listed, though his leadership in pharmacogenomics and clinical trials underscores significant contributions to the field.

Advising & Lab: Supervises PhD student Gustav Beijer. The research group employs LC-MS/MS, microdialysis, and bioinformatics to study drug metabolism and population pharmacokinetics.